Moderna (MRNA) on Thursday announced an agreement with the European Commission to provide several EU nations with up to 24M doses of its mRESVIA vaccine targeted at the respiratory syncytial virus.
As part of the contract, the Cambridge, Massachusetts-based biotech will deliver